ノバルティス

 NVSのチャート


 NVSの企業情報

symbol NVS
会社名 Novartis AG Basel (ノバルティス)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 ノバルティス(Novartis AG)はヘルスケア・ソリューションを提供する持株会社である。同社は医薬品を主としてヘルスケア製品の研究・開発・製造・販売に従事する。同社の事業は医薬品、サンドズ、アルコンとコーポレート活動を含む。医薬品事業は患者と医療提供者のための健康成果を開発するために特許を取得した処方薬を研究、開発、製造、販売、販売する。サンドズ事業は処方薬、有効・執行可能な第三者特許で保護されない医薬品有効成分を開発、製造、販売する。アルコン事業はアイケア製品を研究、開発、製造、販売する。アルコン事業は眼科医療機器と視力ケア製品の提供を行う。同社の製品には、医薬品、腫瘍薬、ジェネリック医薬品、バイオシミラー薬、眼科機器を有する。  ノバルティスはスイスの大手医薬品・バイオテクノロジ―企業。心血管代謝、免疫抑制、皮膚病、網膜、呼吸器など広範な領域で処方薬の研究、開発、生産、販売を展開。また、ジェネリック医薬品の開発、生産、販売に加え、眼科用医療機器、眼科手術器具・消耗品、コンタクトレンズや洗浄液などのアイケア製品も扱う。同社の製品は約180カ国で販売される。  
本社所在地 Lichtstrasse 35 Basel CH-4056 CHE
代表者氏名 Vasant Narasimhan
代表者役職名 Chief Executive Officer Member of the Executive Committee
電話番号 +41 61-324-1111
設立年月日 1895年7月
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 125161人
url www.novartis.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 17697.00000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 240518.10000
売上高 (百万ドル) 53166.00000
企業価値(EV) (百万ドル) 256702.10000
当期純利益 (百万ドル) 12611.00000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Novartis AG (ADR) revenues increased 6% to $53.17B. Net income before extraordinary items increased 65% to $12.61B. Revenues reflect Innovative Medicines segment increase of 8% to $34.89B Alcon segment increase of 6% to $7.15B Other Foreign- segment increase of 6% to $22.17B United States segment increase of 4% to $17.56B Germany segment increase of 13% to $4.18B.

 NVSのテクニカル分析


 NVSのニュース

   Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report  2021/05/17 20:37:50 Benzinga
The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN ) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG’s (NYSE: NVS ) Sandoz from selling a biosimilar of the drug in the U.S. until 2029. The justices turned away Novartis subsidiary Sandoz Inc’s appeal of a lower court decision that upheld the … Full story available on Benzinga.com
   Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks  2021/05/17 16:41:09 Benzinga
Novartis AG (NYSE: NVS ) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Data were presented at the American College of Cardiology's virtual Scientific Session. In the Q1 earnings release, Novartis reported that Entresto missed its primary endpoint to reduce the risk of cardiovascular death and heart failure after acute myocardial … Full story available on Benzinga.com
   Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study  2021/05/03 11:34:58 Benzinga
Novartis AG (NYSE: NVS ) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year data, 6mg Beovu showed non-inferiority in change in best-corrected visual acuity from baseline compared to 2mg Regeneron Pharmaceuticals Inc' s (NASDAQ: REGN ) Eylea (aflibercept). In the KESTREL study, patients in … Full story available on Benzinga.com
   Eli Lil­ly Aban­dons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications  2021/04/27 18:34:25 Benzinga
Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY ) has scrapped its plans to seek approval for mirikizumab in psoriasis . The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG’s (NYSE: NVS ) Cosentyx in a Phase 3 trial last year . AbbVie Inc’s (NYSE: ABBV ) anti-IL-23 antibody Skyrizi and Johnson & Johnson’s (NYSE:
   Truffa Farmaci Lombardia, 5 ospedali San Donato patteggiano, a giudizio Bayer e Novartis  2021/04/27 12:36:25 Investing.com Italy
https://it.investing.com/news/stock-market-news/truffa-farmaci-lombardia-5-ospedali-san-donato-patteggiano-a-giudizio-bayer-e-novartis-1995409
   Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio  2021/04/07 11:08:04 Benzinga
Novartis AG (NYSE: NVS ) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets. During the three-year collaboration, Artios and Novartis will … Full story available on Benzinga.com
   Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know  2021/03/29 15:16:06 Benzinga
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on Benzinga.com
   Novartis corrects chairman's comments about kickbacks case  2021/03/24 15:30:28 Investing.com
https://www.investing.com/news/stock-market-news/novartis-corrects-chairmans-comments-about-kickbacks-case-2456087
   Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer  2021/03/23 13:11:17 Endpoints News
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion
   Autoinjectors Market Is Expected To Exhibit 18.1% CAGR By 2027 | Novartis AG, SHL Medical, Eli Lilly and Company  2021/03/23 12:54:31 OpenPR
Rise in anaphylaxis cases and increases in R&D activities by key players in the market are anticipated to drive the market. Rapid growth has been observed in adoption of biosimilars over branded drugs, which provides low cost treatment options for
   Spenden und viel Lobbying von Roche und Novartis  2021/02/06 12:06:00 SRF Schweizer Radio und Fernsehen
Die USA sind der lukrativste Markt. Auch die Basler Pharmakonzerne machen einiges, dass das so bleibt.
   Global Adalimumab, Infliximab and Etanercept Biosimilars Market Report: COVID-19 Impacts, Growth and Changes - Forecast to 2030  2021/02/05 13:00:00 Benzinga
DUBLIN , Feb. 5, 2021 /PRNewswire/ -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion and Mylan. The global adalimumab, infliximab, and etanercept market is expected to grow from $2.2 billion in 2019 to $2.27 billion in 2020 at a compound annual growth rate (CAGR) of 3.24%. The market is expected to recover and reach $7.50 billion in 2023 at a CAGR of 48.94%. The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules such as Humira, Remicade and Enbrel, respectively.
   Global Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Insights Report 2020 Featuring Takeda Oncology, Epizyme, Vyriad, Novartis, DNAtrix, Pfizer, Oncoceutics & Istari Oncology - ResearchAndMarkets.com  2021/02/05 12:49:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight - 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2020," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape
   ALK Positive Lung Cancer Treatment Market Major Players F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, TP Therapeutics, Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.  2021/02/05 09:09:26 OpenPR
CMI published a business research report on ALK Positive Lung Cancer Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2020–2026. ALK Positive Lung Cancer Treatment Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread
   CAR T Cell Therapy Market Sales Volume, Status, Growth, Opportunities And World Market Share Of 2026 | Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.)  2021/02/05 03:50:29 OpenPR
"CAR T Cell Therapy Market″ Report evaluated the historical and current performance of the market, especially highlighting the key trends and growth opportunities. CAR T Cell Therapy market report discussed this scenario of market size with reference to volume and

 関連キーワード  (医薬品 米国株 ノバルティス NVS )

 twitter  (公式ツイッターやCEOツイッターなど)

NVS動画